Clement Therapeutics

Clement Therapeutics is a private biotechnology company focused on developing novel therapeutics for respiratory and inflammatory diseases. As a portfolio company of TCG Labs Soleil, Clement is advancing a single-asset program: a bispecific monoclonal antibody (BsAb) targeting both thymic stromal lymphopoietin (TSLP) and interleukin-33 (IL-33). This dual-targeting approach is designed to address the underlying drivers of chronic obstructive pulmonary disease (COPD), asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). The program is currently in the IND-enabling stage of development, leveraging TCG Labs Soleil's integrated R&D and venture ecosystem to progress toward clinical proof of concept.